StockData
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. (STOK) stock

STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30173% above fair value
$26.41−0.22 (-0.83%)

Close on Nov 17, 2026Market cap $1.70BP/E –Yield –

Stoke Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Stoke Therapeutics's price to book ratio was 5.0× on Nov 11, 2026, against 5.5× a year earlier. Over the last 5 years it ranged from 0.9× to 6.1×, with a median of 2.6×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20265.0×−0.7
2025Dec 31, 20255.7×+3.2
2024Dec 31, 20242.5×+1.2
2023Dec 29, 20231.3×−0.4
2022Dec 30, 20221.8×−1.9
2021Dec 31, 20213.7×−7.0
2020Dec 31, 202010.7×+6.8
2019Dec 31, 20194.0×–

More Stoke Therapeutics figures

See a number that looks wrong?